Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells

Area of Science:

• Immunology
• Rheumatology
• Cell Biology

Background:

• Scleroderma (systemic sclerosis; SSc) is an autoimmune disease characterized by fibrosis in skin and organs.
• Fibrosis involves excessive extracellular matrix production and loss of epithelial structures, resembling scar formation.
• Fibroblasts are key connective tissue cells implicated in SSc pathogenesis.

Purpose of the Study:

• To review fibroblast biology within the context of systemic sclerosis.
• To highlight the role of fibroblast effector cells in SSc-related fibrosis.
• To explore how fibroblast heterogeneity and myofibroblast diversity may explain clinical variations in SSc.

Main Methods:

• Literature review focusing on fibroblast biology and systemic sclerosis.
• Analysis of mechanisms driving fibroblast activation and differentiation into myofibroblasts.
• Exploration of the origins and regulatory pathways of myofibroblasts in SSc.

Main Results:

• Fibroblasts are crucial effector cells in SSc, contributing to fibrosis.
• Myofibroblast differentiation is a hallmark of SSc, but its precise mechanisms and cellular origins remain under investigation.
• Heterogeneity in fibroblast properties and myofibroblast origins likely contributes to the diverse clinical manifestations of SSc.

Conclusions:

• Fibroblast biology is central to understanding systemic sclerosis pathogenesis.
• The heterogeneity of fibroblasts and myofibroblasts offers potential targets for novel SSc therapies.
• Further research into fibroblast origins and regulatory pathways is warranted to address clinical diversity in SSc.